<?xml version="1.0" encoding="UTF-8"?>
<ref id="B88-pharmaceuticals-14-00381">
 <label>88.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Chen</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Luo</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Xu</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Liew</surname>
    <given-names>O.W.</given-names>
   </name>
   <name>
    <surname>Zhu</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Puah</surname>
    <given-names>C.M.</given-names>
   </name>
   <name>
    <surname>Shen</surname>
    <given-names>X.</given-names>
   </name>
  </person-group>
  <article-title>Binding interaction of quercetin-3-β-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: Structure–activity relationship studies reveal salient pharmacophore features</article-title>
  <source>Bioorganic Med. Chem.</source>
  <year>2006</year>
  <volume>14</volume>
  <fpage>8295</fpage>
  <lpage>8306</lpage>
  <pub-id pub-id-type="doi">10.1016/j.bmc.2006.09.014</pub-id>
 </element-citation>
</ref>
